Scilex Holding Company
NASDAQ:SCLXDrug Manufacturers - General
-$0.17 today
- Market cap
- $53.83M
- Beta
- 1.71
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$60.90
Volume 0.00M
Average 0.13M
SCLX EBITDA Margin
EBITDA as a percentage of revenue.
Scilex Holding CompanyNASDAQ: SCLX
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to -452.8%
EBITDA Margin was -452.8% in Q1 FY2026, down 1.3 pp from a year earlier. On a trailing-twelve-month basis it was -1105.5%, down 974.2 pp year over year. Over 3 fiscal years it narrowed by 1158.7 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 1 analysts of -84.9% for the fiscal year ending Dec 2026, up from -1183.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -452.8%+402.9 pp QoQ
- Last fiscal yearDec 2025
- -1183.2%-1065.1 pp YoY
- LTMMar 2026
- -1105.5%-974.2 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -1183.2%
- Year-over-year change
- -1065.1pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -1183.2% | -1065.1pp |
| FY2024 | 2024-12-31 | -118.0% | +115.4pp |
| FY2023 | 2023-12-31 | -233.4% | -209.0pp |
| FY2022 | 2022-12-31 | -24.5% | +208.2pp |
| FY2021 | 2021-12-31 | -232.7% | — |
EBITDA Margin vs competitors
How SCLX compares with its peers on the latest reported figures
- SCLX's LTM Mar 2026 EBITDA Margin of -1105.5% is the 7th highest of the 8 companies compared; the peer median is -732.1%.
- Its year-over-year change of -974.2 pp is the 6th highest of 7, against a peer median of -203.3 pp.
- Over three fiscal years its change of -1158.7 pp compares with a peer median of -104.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 102.6% | +184.0 pp | +219.6 pp | |
| LTM Mar 2026 | -427.9% | +95.5 pp | +175.4 pp | |
| LTM Mar 2026 | -632.1% | -502.0 pp | -541.5 pp | |
CTORCitius Oncology, Inc. | LTM Mar 2026 | -732.1% | — | — |
| LTM Mar 2026 | -859.3% | +600.4 pp | +13170.1 pp | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -874.0% | -638.6 pp | -384.3 pp |
| LTM Mar 2026 | -1105.5% | -974.2 pp | -1158.7 pp | |
| FY2025 | -125425.9% | -77690.7 pp | -122786.1 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding SCLX) | -732.1% | -203.3 pp | -104.5 pp | |
Competitors are the stored peer set for SCLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 31.32M | 38.03M | 46.74M | 56.59M | 30.25M |
| Cost of Revenue | 3.63M | 10.8M | 15.68M | 16.69M | 15.22M |
| Gross Profit | 27.68M | 27.24M | 31.06M | 39.9M | 15.03M |
| Gross Margin | 88.4% | 71.6% | 66.5% | 70.5% | 49.7% |
| Research & Development | 9.2M | 9.05M | 12.75M | 9.64M | 20.71M |
| Selling, General & Admin | 50.58M | 64.9M | 119.64M | 119.02M | 266.63M |
| Operating Expenses | 63.52M | 77.87M | 136.49M | 123.3M | 287.34M |
| Depreciation & Amortization | 3.78M | 4.45M | 4.15M | 4.05M | 4.62M |
| EBITDA | (72.88M) | (9.3M) | (109.1M) | (66.8M) | (357.95M) |
| EBITDA Margin | -232.7% | -24.5% | -233.4% | -118.0% | -1183.2% |
| Operating Income | (35.84M) | (50.63M) | (105.43M) | (83.4M) | (272.3M) |
| Operating Margin | -114.4% | -133.1% | -225.6% | -147.4% | -900.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 11.76M | 9.6M | 1.07M | 1.96M | 11.46M |
| Other Income / Expenses | (52.58M) | 27.27M | (8.89M) | 10.59M | (101.72M) |
| Income Before Tax | (88.42M) | (23.36M) | (114.32M) | (72.81M) | (374.03M) |
| Pre-Tax Margin | -282.3% | -61.4% | -244.6% | -128.7% | -1236.3% |
| Income Tax Expense | 5K | 4K | 13K | (1K) | 26K |
| Net Income | (88.42M) | (23.36M) | (114.33M) | (72.81M) | (358.73M) |
| Net Margin | -282.4% | -61.4% | -244.6% | -128.7% | -1185.8% |
| EPS (Basic) | (23.29) | (6.09) | (44.85) | (19.43) | (36.48) |
| EPS (Diluted) | (23.29) | (6.09) | (44.85) | (19.43) | (36.48) |
| Weighted Avg Shares | 3.8M | 3.83M | 3.72M | 6.95M | 11.03M |
| Weighted Avg Shares (Diluted) | 3.8M | 3.83M | 3.72M | 6.95M | 11.03M |
Scilex Holding Company
NASDAQ:SCLX
Intrinsic Alpha fair value
Locked
Current Price
$6.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.